Please login to the form below
psoriatic arthritis
This page shows the latest psoriatic arthritis news and features for those working in and with pharma, biotech and healthcare.
Novartis gains label boost for Cosentyx
Cosentyx has been in the psoriatic arthritis (PsA) market for almost four years now, and has also established itself in plaque psoriasis and ankylosing spondylitis. ... The lack of long-term efficacy for psoriatic arthritis treatments causes patients to
Latest news
-
BMS psoriasis drug hits the mark in phase II
which brought in $1.3bn in sales last year in psoriasis and psoriatic arthritis. ... Pfizer’s Xeljanz (tofacitinib) has been approved for psoriatic arthritis but was turned down by the FDA for psoriasis in 2015.
-
Gilead, Galapagos JAK inhibitor clears phase II test
In the TORTUGA trial, filgotinib met its clinical objective of reducing disease activity scores compared to placebo in patients with AS, a severe form of arthritis affecting the spine, with more ... Like filgotinib, upadacitinib is also being tested in a
-
Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar and Xeljanz
Xejanz is already approved in three other indications in the EU: in combination with methotrexate (MTX), in moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, ... MTX for active psoriatic arthritis in
-
Boehringer beefs up biologics capacity with €230m investment
That includes its portfolio of biosimilar drugs, as well as novel candidates such as AbbVie-partnered interleukin-23 inhibitor risankizumab – in phase III trials in psoriasis and psoriatic arthritis – and
-
AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib
AbbVie’s run of positive results for upadacitinib in rheumatoid arthritis continues with new data at EULAR on patients’ experience with the drug. ... Meanwhile, following the same path as Xeljanz, upadacitinib is also being tested in a string of
More from news
Approximately 13 fully matching, plus 101 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other inflammatory conditions. ... AbbVie has five trials on the go in rheumatoid arthritis and will be filing in that indication before the end of the year.
-
The good, the bad and the ugly
Elsewhere, Celgene has seen large growth in 2017 (46%) - driven by sales of Otezla, the first oral small molecule to be approved for psoriasis and psoriatic arthritis. ... Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic
-
Deal Watch December 2016
510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... The Scandinavian company, Nuevolution, uses its drug discovery platform Chemetics to discover novel small
-
Taking a strategic approach
Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of
-
Pharma deals during July 2014
Cimzia, a pegylated antibody fragment that blocks tumour necrosis factor alpha, is currently indicated for several disorders including Crohn's disease, rheumatoid arthritis and psoriatic arthritis. Based on promising phase 2
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
emotive adds to medical team with new Scientific Lead and Associate Medical Writer
Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease,
-
Lucid win PMEA Support Agency of the Year 2016
management of psoriatic arthritis.Judges’ comments: “In taking a different approach, this work stands out from the many support programmes already out there.
-
Lucid make the shortlist in all of the four categories they entered for the PMEA programme 2016
um: Changing clinical behaviour on a global scale to improve standards of care in the management of psoriatic arthritis. .
-
Millefeuille
This story of hope charts Élodie’s physical and mental struggles with psoriasis and psoriatic arthritis. ... For more information please visit http://bedrock-health.com/millefeuille/. This story of hope charts Élodie’s physical and mental struggles
-
Infographic: Spondyloarthritis
Overview of spondyloarthritis patient profiles and treatment pathways. Spondyloarthritis is the name for a family of arthritis causing inflammatory rheumatic diseases; including axial spondyloarthritis, psoriatic arthritis and akylosing spondylitis,
More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.
Featured jobs
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Senior Medical Writer
-
Great salary and benefits
-
Senior Medical Writer
-
Up to £50, 000 with Benefits
-
Project Manager/ Account Manager
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Digital Account Director
-
Salary TBC
Subscribe to our email news alerts
- Drug launches to watch in 2019
- Welcome to the Communique Awards - Communiqué Awards 2018
- ‘Inflexible’ NICE blocking access to rare disease drugs
- GW Pharma's cannabis-based medicine to be tested in dementia
- Immuno-oncology in 2019: the rapid evolution continues
- 2019: CRISPR and therapeutic gene editing comes of age
- NICE knocks back BioMarin’s Batten disease drug
- Amgen, Servier start second phase 3 trial of heart failure hope
- The importance of co-creation with patients
- McCann Health's next challenge: creative differentiation
- Greater Manchester backs move to outcome-based payment
- Merck & Co to buy IO specialists Immune Design for $300m
PMHub
Skills in Healthcare
At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...
Latest intelligence
- The importance of co-creation with patients
- Overcoming the barriers...
- Three billboards on the road to multichannel
- Chris Ross examines the trends driving multichannel communication in 2019...
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Quick links
Infographics
